-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 8, the State Food and Drug Administration urgently approved Tengsheng Huachuang Medical Technology (Beijing) Co.
, Ltd.
's new coronavirus neutralizing antibody combined therapy drug Ambavirimab injection (BRII-196) and Romisvirimab injection Liquid (BRII-198) registration application
.
This is China's first approved new coronavirus neutralizing antibody combination therapy with independent intellectual property rights
.
It is reported that the State Food and Drug Administration, in accordance with the relevant provisions of the Drug Administration Law, in accordance with the special drug approval procedures, conducts emergency review and approval, and approves the above two drugs to be used in combination to treat mild and common types with progress to severe (including hospitalization or Death) Adults and adolescents (12-17 years old, weight ≥40kg) with high-risk factors, patients with novel coronavirus infection (COVID-19)
.
Among them, adolescents (12-17 years old, weight ≥40kg) indication population are conditional approval
.